| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3389 |
| Trial ID | NCT05798117 |
| Disease | Lupus Nephritis | Systemic Lupus Erythematosus |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | YTB323|Rapcabtagene Autoleucel |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
| Year | 2023 |
| Country | Spain |
| Company sponsor | Novartis Pharmaceuticals |
| Other ID(s) | CYTB323G12101|2022-001796-14 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||